Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. trimmed its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 4.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,320,652 shares of the biotechnology company’s stock after selling 67,922 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned 4.94% of Arcturus Therapeutics worth $41,640,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. MetLife Investment Management LLC lifted its stake in Arcturus Therapeutics by 66.3% in the 1st quarter. MetLife Investment Management LLC now owns 12,327 shares of the biotechnology company’s stock valued at $332,000 after buying an additional 4,915 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Arcturus Therapeutics by 190.3% during the first quarter. Dimensional Fund Advisors LP now owns 217,572 shares of the biotechnology company’s stock valued at $5,866,000 after acquiring an additional 142,633 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Arcturus Therapeutics by 0.5% in the first quarter. Vanguard Group Inc. now owns 1,153,513 shares of the biotechnology company’s stock valued at $31,099,000 after acquiring an additional 6,291 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Arcturus Therapeutics by 1.8% in the first quarter. Federated Hermes Inc. now owns 3,761,900 shares of the biotechnology company’s stock worth $101,421,000 after acquiring an additional 66,971 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Arcturus Therapeutics by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 154,551 shares of the biotechnology company’s stock worth $4,167,000 after acquiring an additional 3,704 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Trading Down 1.3 %

Shares of ARCT opened at $25.98 on Friday. The firm has a 50-day moving average price of $35.19 and a 200 day moving average price of $29.73. Arcturus Therapeutics Holdings Inc. has a 12-month low of $17.52 and a 12-month high of $43.81. The firm has a market capitalization of $699.25 million, a P/E ratio of -24.98 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($1.69) by $1.37. The business had revenue of $33.99 million during the quarter, compared to analysts’ expectations of $64.14 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. Equities research analysts predict that Arcturus Therapeutics Holdings Inc. will post -1.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 17,435 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $35.02, for a total transaction of $610,573.70. Following the completion of the transaction, the chief operating officer now directly owns 473,448 shares in the company, valued at approximately $16,580,148.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 13.80% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on ARCT shares. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. Citigroup raised their price target on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, February 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $61.33.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.